Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-normal
Interventions: DRUG: eribulin mesylate
Sponsor: Eisai Inc.